- Home
- CHRS vs XBIT Comparison
CHRS vs XBIT Comparison
Compare CHRS & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- XBIT
- Stock Information
- Founded
- CHRS 2010
- XBIT 2005
- Country
- CHRS United States
- XBIT United States
- Employees
- CHRS N/A
- XBIT N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- XBIT Pharmaceuticals and Biotechnology
- Sector
- CHRS Health Care
- XBIT Health Care
- Exchange
- CHRS Nasdaq
- XBIT Nasdaq
- Market Cap
- CHRS 191.3M
- XBIT 194.5M
- IPO Year
- CHRS 2014
- XBIT 2015
- Fundamental
- Price
- CHRS $1.24
- XBIT $3.65
- Analyst Decision
- CHRS Strong Buy
- XBIT
- Analyst Count
- CHRS 4
- XBIT 0
- Target Price
- CHRS $5.38
- XBIT N/A
- AVG Volume (30 Days)
- CHRS 2.0M
- XBIT 64.7K
- Earning Date
- CHRS 03-12-2025
- XBIT 03-14-2025
- Dividend Yield
- CHRS N/A
- XBIT N/A
- EPS Growth
- CHRS N/A
- XBIT N/A
- EPS
- CHRS N/A
- XBIT N/A
- Revenue
- CHRS $304,340,000.00
- XBIT N/A
- Revenue This Year
- CHRS $2.47
- XBIT N/A
- Revenue Next Year
- CHRS N/A
- XBIT N/A
- P/E Ratio
- CHRS N/A
- XBIT N/A
- Revenue Growth
- CHRS 44.19
- XBIT N/A
- 52 Week Low
- CHRS $0.66
- XBIT $3.51
- 52 Week High
- CHRS $2.87
- XBIT $9.96
- Technical
- Relative Strength Index (RSI)
- CHRS 37.51
- XBIT 30.13
- Support Level
- CHRS $1.38
- XBIT $3.60
- Resistance Level
- CHRS $1.45
- XBIT $4.00
- Average True Range (ATR)
- CHRS 0.13
- XBIT 0.26
- MACD
- CHRS -0.04
- XBIT 0.06
- Stochastic Oscillator
- CHRS 4.50
- XBIT 4.67
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About XBIT XBiotech Inc.
XBiotech Inc is a United States-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-IL-1 a therapeutic antibody as a treatment for cancer. Geographically, all of its operations are in the United States.